Recombinant Human T-Cell Immunoreceptor With Ig And Itim Domains (TIGIT) Protein (hFc-Myc), Active
Beta LifeScience
SKU/CAT #: BLC-05867P
Greater than 95% as determined by SDS-PAGE.
Activity FACS assay shows that Human TIGIT can bind to 293F cell overexpressing human CD155. Biological Activity Assay
The purity of Human TIGIT was greater than 95% as determined by SEC-HPLC
Recombinant Human T-Cell Immunoreceptor With Ig And Itim Domains (TIGIT) Protein (hFc-Myc), Active
Beta LifeScience
SKU/CAT #: BLC-05867P
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
| Description | Recombinant Human T-Cell Immunoreceptor With Ig And Itim Domains (TIGIT) Protein (hFc-Myc), Active is produced by our Mammalian cell expression system. This is a protein fragment. |
| Purity | Greater than 95% as determined by SDS-PAGE and HPLC. |
| Endotoxin | Less than 1.0 EU/ug as determined by LAL method. |
| Activity | FACS assay shows that Human TIGIT can bind to 293F cell overexpressing human CD155. |
| Uniprotkb | Q495A1 |
| Target Symbol | TIGIT |
| Synonyms | (VSIG9)(VSTM3) |
| Species | Homo sapiens (Human) |
| Expression System | Mammalian cell |
| Tag | C-hFc-Myc |
| Target Protein Sequence | MMTGTIETTGNISAEKGGSIILQCHLSSTTAQVTQVNWEQQDQLLAICNADLGWHISPSFKDRVAPGPGLGLTLQSLTVNDTGEYFCIYHTYPDGTYTGRIFLEVLESSVAEHGARFQIP |
| Expression Range | 22-141aa |
| Protein Length | Partial |
| Mol. Weight | 43.2 kDa |
| Form | Lyophilized powder |
| Buffer | Lyophilized from a 0.2 μm filtered PBS, 6% Trehalose, pH 7.4 |
| Reconstitution | Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%. |
| Storage | 1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C. |
| Notes | Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week. |
Target Details
| Target Function | Binds with high affinity to the poliovirus receptor (PVR) which causes increased secretion of IL10 and decreased secretion of IL12B and suppresses T-cell activation by promoting the generation of mature immunoregulatory dendritic cells. |
| Subcellular Location | Cell membrane; Single-pass type I membrane protein. |
| Database References | |
| Tissue Specificity | Expressed at low levels on peripheral memory and regulatory CD4+ T-cells and NK cells and is up-regulated following activation of these cells (at protein level). |
Gene Functions References
- The activation of PD-1 and TIGIT may exert negative regulatory effects and inhibit the immune response to cancer cells, resulting in immune escape of cancer cells. PMID: 30262800
- These findings highlight the importance of the TIGIT/CD226/PVR axis as an immune checkpoint barrier that could hinder future "cure" strategies requiring potent HIV-specific CD8(+) T cells PMID: 28084312
- High expression of TIGIT and Helios identifies CD4+ T cells with impaired immunological functions, primarily among patients with an advanced stage of Sezary syndrome. PMID: 27592800
- Natural killer cells and cytotoxic T cells express both TIGIT and DNAM-1 receptors, and in certain cases their effector functions are dictated by TIGIT or DNAM-1 signaling. Agonist and antagonist antibodies targeting either TIGIT or DNAM-1 present many therapeutic options for diseases spanning from cancer to auto-immunity. (Review) PMID: 28035916
- TIGIT contributes to functional T-cell impairment and associates with poor clinical outcome in acute myelogenous leukemia. The study suggests that blockade of TIGIT to restore T-cell function and antitumor immunity may represent a novel effective leukemia therapeutic. PMID: 26763253
- Blimp-1 binds to the promoters of PD-1 and TIGIT and positively regulates their expression in patients with acute myeloid leukemia. PMID: 28629373
- Data show that gastric cancer cells inhibit T-cell metabolism through CD155/TIGIT signaling. PMID: 28883004
- Our data provide important structural and biochemical determinants responsible for the recognition of nectin-2 by TIGIT. PMID: 27978489
- TIGIT is a powerful negative regulator of CD4(+) T cells in systemic lupus erythematosus. PMID: 28108989
- TIGIT signaling in NK cells after MDSC coculture led to a decrease in the phosphorylation of ZAP70/Syk and ERK1/2. PMID: 27503932
- energetic basis for the TIGIT/nectin-2 interaction and revealed that an "aromatic key" of nectin-2 is critical for this interaction, whereas variations in the lock were tolerated. PMID: 28515320
- TIGIT-positive circulating follicular helper T cells display robust B-cell help functions: potential role in sickle cell alloimmunization. PMID: 26250578
- implying that TIGIT exerts immunosuppressive effects by competing with DNAM-1 for the same ligand, CD155 PMID: 26842126
- These findings identify TIGIT as a novel marker of dysfunctional HIV-specific T cells PMID: 26741490
- This study shows that HBZ-induced TIGIT plays a pivotal role in attenuating host immune responses and shaping a microenvironment favorable to human T-cell leukemia virus type 1. PMID: 26735971
- a novel mechanism that links TIGIT expression with NK-cell functional heterogeneity, and this mechanism might partially explain why individuals have different susceptibilities to infection, autoimmune disease, and cancer. PMID: 26171588
- Human regulatory T cells expressing the receptors TIGIT and CD226 display widely divergent phenotypes in regard to expansion and activation. PMID: 25994968
- TIGIT and PD-1 blockade additively increased proliferation, cytokine production, and degranulation of tumor-antigen-specific CD8 T cells and CD8 TILs. TIGIT and PD-1 regulate the expansion and function of these T cells in melanoma. PMID: 25866972
- The results identify a bacterium-dependent, tumor-immune evasion mechanism in which tumors exploit the Fap2 protein of F. nucleatum to inhibit immune cell activity via TIGIT. PMID: 25680274
- Findings suggest that TIGIT is a key checkpoint inhibitor of chronic antiviral and antitumor responses through impairing CD226 function when disrupting its homodimerization. PMID: 25465800
- TIGIT/PVR ligation signaling mediates suppression of IFN-gamma production via the NF-kappaB pathway. PMID: 24817116
- TIGIT is phosphorylated at its cytoplasmic tail after its ligation with PVR. PMID: 23154388
- The Tim-3 pathway appears to control regulatory (Treg) and effector T cell balance via altering cell proliferation and apoptosis during hepatitis C virus infection. PMID: 22706088
- TIGIT can inhibit T cell functions by competing with CD226 and can also directly inhibit T cells in a T cell-intrinsic manner. PMID: 22427644
- data suggest a cis-trans receptor clustering mechanism for cell adhesion and signaling by the TIGIT/PVR complex and provide structural insights into how the PVR family of immunoregulators function PMID: 22421438
- that soluble Vstm3 attenuates T-cell responses in vitro and in vivo PMID: 21416464
- TIGIT exerts immunosuppressive effects by binding to poliovirus receptor and modulating cytokine production by dendritic cells. PMID: 19011627
- a novel immunoreceptor, Washington University Cell Adhesion Molecule, which is expressed on human follicular B helper T cells, was described. PMID: 19197944
- TIGIT counter inhibits the NK-mediated killing of tumor cells and protects normal cells from NK-mediated cytotoxicity thus providing an "alternative self" mechanism for MHC class I inhibition. PMID: 19815499
